Intellipharmaceutics IPCIF Stock
Intellipharmaceutics Price Chart
Intellipharmaceutics IPCIF Financial and Trading Overview
Intellipharmaceutics stock price | 0.06 USD |
Previous Close | 0.04 USD |
Open | 0.06 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0.06 - 0.06 USD |
52 Week Range | 0.01 - 0.11 USD |
Volume | 1.04K USD |
Avg. Volume | 5.23K USD |
Market Cap | 2.13M USD |
Beta (5Y Monthly) | 0.997113 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.09 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
IPCIF Valuation Measures
Enterprise Value | 3.62M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.915616 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 11.725 |
Enterprise Value/EBITDA | -1.656 |
Trading Information
Intellipharmaceutics Stock Price History
Beta (5Y Monthly) | 0.997113 |
52-Week Change | -45.45% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.11 USD |
52 Week Low | 0.01 USD |
50-Day Moving Average | 0.05 USD |
200-Day Moving Average | 0.07 USD |
IPCIF Share Statistics
Avg. Volume (3 month) | 5.23K USD |
Avg. Daily Volume (10-Days) | 8.75K USD |
Shares Outstanding | 33.09M |
Float | 28.84M |
Short Ratio | 0.39 |
% Held by Insiders | 1.76% |
% Held by Institutions | 11.09% |
Shares Short | 714K |
Short % of Float | 3.35% |
Short % of Shares Outstanding | 3.25% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | November 30, 2022 |
Most Recent Quarter (mrq) | February 28, 2023 |
Next Fiscal Year End | November 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -770.74% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -85.33% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 308.66K USD |
Revenue Per Share (ttm) | 0.009 USD |
Quarterly Revenue Growth (yoy) | 291.19% |
Gross Profit (ttm) | 65.73K USD |
EBITDA | -2184783 USD |
Net Income Avi to Common (ttm) | -2367160 USD |
Diluted EPS (ttm) | -0.12 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 69.55K USD |
Total Cash Per Share (mrq) | 0.002 USD |
Total Debt (mrq) | 2.3M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.059 |
Book Value Per Share (mrq) | -0.33 |
Cash Flow Statement
Operating Cash Flow (ttm) | -841818 USD |
Levered Free Cash Flow (ttm) | -101801 USD |
Profile of Intellipharmaceutics
Country | United States |
State | ON |
City | Toronto |
Address | 30 Worcester Road |
ZIP | M9W 5X2 |
Phone | 416 798 3001 |
Website | https://www.intellipharmaceutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 11 |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
Q&A For Intellipharmaceutics Stock
What is a current IPCIF stock price?
Intellipharmaceutics IPCIF stock price today per share is 0.06 USD.
How to purchase Intellipharmaceutics stock?
You can buy IPCIF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Intellipharmaceutics?
The stock symbol or ticker of Intellipharmaceutics is IPCIF.
Which industry does the Intellipharmaceutics company belong to?
The Intellipharmaceutics industry is Biotechnology.
How many shares does Intellipharmaceutics have in circulation?
The max supply of Intellipharmaceutics shares is 33.09M.
What is Intellipharmaceutics Price to Earnings Ratio (PE Ratio)?
Intellipharmaceutics PE Ratio is now.
What was Intellipharmaceutics earnings per share over the trailing 12 months (TTM)?
Intellipharmaceutics EPS is -0.09 USD over the trailing 12 months.
Which sector does the Intellipharmaceutics company belong to?
The Intellipharmaceutics sector is Healthcare.